A-65317 | 122224-84-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: A-65317
• 英文别名: N-[1-[[3-Cyclohexyl-1-(3-ethyl-2-oxo-1,3-oxazolidin-5-yl)-1-hydroxypropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-N'-[2-(2-methoxyethoxymethoxy)ethyl]-N'-methyl-2-(phenylmethyl)butanediamid；(2R)-2-benzyl-N-[(2S)-1-[[(1R,2S)-3-cyclohexyl-1-[(5S)-3-ethyl-2-oxo-1,3-oxazolidin-5-yl]-1-hydroxypropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-N'-[2-(2-methoxyethoxymethoxy)ethyl]-N'-methylbutanediamide
• CAS: 122224-84-4
• 化学式: C₃₈H₅₈N₆O₉
• 分子量: 742.913
• InChiKey: JZRFAIHFMIECQR-AJISXOSTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  53
• 可旋转键数：
  23
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.66
• 拓扑面积：
  185
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  在 N-甲基吗啉 、 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 37.0h， 生成 A-65317
  参考文献：
  名称：

  Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action

  摘要：

  Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.

  DOI：

  10.1021/jm00169a024

文献信息

• Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action
  作者：Saul H. Rosenberg、Keith W. Woods、Hing L. Sham、Hollis D. Kleinert、Donald L. Martin、Herman Stein、Jerome Cohen、David A. Egan、Barbara Bopp

  DOI：10.1021/jm00169a024

  日期：1990.7

  Incorporation of nonreactive polar functionalities at the C- and N-termini of renin inhibitors led to the development of a subnanomolar compound (21) with millimolar solubility. This inhibitor demonstrated excellent efficacy and a long duration of action upon intravenous administration to monkeys. While activity was also observed intraduodenally, a comparison of the blood pressure responses indicated low bioavailability. Subsequent experiments in rats showed that, although the compound was absorbed from the gastrointestinal tract, extensive liver extraction severely limited bioavailability.